Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Phase 3
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Device: Gereic Dry Powder Inhaler
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06274801
- Locations
- 🇩🇰
Aarhus Universiteshospital, Aarhus, Denmark
🇸🇬National University Heart Centre, Singapore, Singapore
🇪🇸Hospital Clinic I Provincial, Barcelona, Spain
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Phase 3
Recruiting
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT05934526
- Locations
- 🇨🇴
Fundación Neumologica Colombiana, Bogotá, Colombia
🇬🇷ATTIKON University Hospital, 2nd Critical Care Department, Athens, Greece
🇬🇷Onassis Cardiac Surgery Center, Kallithéa, Greece
© Copyright 2025. All Rights Reserved by MedPath